Ams W, Cuvelier ME, Berset C: Use of absolutely free radical strategy to evaluate antioxidant activity. Lebensm-Wiss Technol 1995, 28:25?0. 47. TrkB Activator manufacturer Chiang LC, Chiang W, Chang MY, Ng LT, Lin CC: Antileukimic activity selected all-natural goods in Taiwan. Am J Chin Med 2003, 31:37?six. 48. Repetto G, del Peso A, Zurita JL: Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008, three:1125?131. 49. Lee CC, Houghton P: Cytotoxicity of plants from Malaysia and Thailand utilised traditionally to treat cancer. J Ethanopharmacol 2005, 100:237?43. 50. Boik J: All-natural compounds in cancer therapy. Minnesota, USA: Oregon Healthcare Press; 2001. 51. Sri Nurestri AM, Sim KS, Norhanom AW, Hashim Y: Phytochemical and cytotoxic investigations of Pereskia grandifolia Haw. (Cactaceae) leaves. J Biol Sci 2009, 9:488?93. 52. Takeara R, Jimenez Computer, Wilke DV, Odorico de Moraes M, Pessoa C, Peporine Lopes N, Lopes JLC, Monteiro da Cruz Lotufo T, Costa Lotufo LV: Antileukemic effects of Didemnum psammatodes (Tunicata: Ascidiacea) constituents. Comp Biochem Physiol A Mol Integr Physiol 2008, 151:363��369. 53. Miret S, De Groene EM, Klaffke W: Comparison of in vitro assays of cellular toxicity inside the human hepatic cell line HepG2. J Biomol Screen 2006, 11:184?93. 54. Syed Abd Rahman SN, Abdul Wahab N, Abd Malek SN: In vitro morphological assessment of apoptosis induced by antiproliferative constituents in the rhizomes of Curcuma zedoria. Evid Primarily based Complement Alternat Med 2013, 2013:14.doi:10.1186/1472-6882-13-243 Cite this article as: Phang et al.: Antioxidant prospective, cytotoxic activity and total phenolic content material of Alpinia pahangensis rhizomes. BMC Complementary and Alternative Medicine 2013 13:243.Submit your subsequent manuscript to BioMed Central and take full benefit of:?Convenient on the web submission ?Thorough peer review ?No space constraints or colour figure charges ?Quick publication on acceptance ?Inclusion in PubMed, CAS, Scopus and Google Scholar ?Analysis which can be freely readily available for redistributionSubmit your manuscript at biomedcentral/submit
Drugs R D (2014) 14:177?84 DOI 10.1007/s40268-014-0055-ORIGINAL Investigation ARTICLESwitching a-Glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Risk Elements in Sort two Diabetic Japanese PatientsNatsuyo Hariya ?Kazuki Mochizuki ?Seiya Inoue ?Miyoko Saito ?Masahiro RORγ Inhibitor Storage & Stability Fuchigami Toshinao Goda ?Takeshi Osonoi?Published online: 31 July 2014 ?The Author(s) 2014. This article is published with open access at SpringerlinkAbstract Background and Objectives In this study we examined the effects of switching a-glucosidase inhibitors (a-GI) from acarbose or voglibose to miglitol on glucose fluctuations and circulating concentrations of cardiovascular illness danger factors, like soluble adhesion molecules (sE-selectin, sICAM-1 and sVCAM-1), a chemokine monocyte chemoattractant protein (MCP)-1, plasminogen activator inhibitor-1, and fatty acid-binding protein four, in form 2 diabetic individuals for 3 months. Solutions We enrolled 47 Japanese sufferers with variety two diabetes, with HbA1c levels with 7.26 ?0.five (imply ?common deviation), and who have been treated with the highest authorized dose of acarbose (one hundred mg/meal) or voglibose (0.three mg/meal) in mixture with insulin or sulfonylurea.N. Hariya Division of Engineering, Interdisciplinary Graduate College of Medicine and Engineering, University of Yamanashi, Kofu, Japan K. Mochizuki ?S. Inoue ?T. Goda Division of Food and Nutrition.
